<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02511613</url>
  </required_header>
  <id_info>
    <org_study_id>OHR-1501</org_study_id>
    <nct_id>NCT02511613</nct_id>
  </id_info>
  <brief_title>Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration</brief_title>
  <official_title>A Study of Safety, Functional and Anatomical Effect of Squalamine Lactate Ophthalmic Solution, 0.2% Administered Twice Daily in Subjects With Neovascular Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohr Pharmaceutical Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohr Pharmaceutical Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate anatomical and functional effect of combination
      therapy of Squalamine Lactate Ophthalmic Solution, 0.2% administered twice daily with monthly
      ranibizumab intravitreal injections in patients with choroidal neovascularization due to AMD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with age-related macular degeneration who meet inclusion and exclusion criteria will
      be randomized to receive monthly intravitreal injections of ranibizumab (Lucentis®) with
      either Squalamine Lactate Ophthalmic solution 0.2% or placebo eye drops twice a day for 6
      months. Subjects will be evaluated with clinical and imaging techniques.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Company decision
  </why_stopped>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of combination therapy of ranibizumab monthly intravitreal injections with Squalamine Lactate Ophthalmic Solution, 0.2% on anatomy and function as assessed by retinal imaging and ETDRS BCVA in subjects with Age-Related Macular Degeneration</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Age-Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Monthly intravitreal ranibizumab plus Placebo Ophthalmic solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Monthly intravitreal ranibizumab plus Squalamine Lactate Ophthalmic solution 0.2%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Squalamine Lactate Ophthalmic Solution, 0.2%</intervention_name>
    <description>Squalamine Lactate Ophthalmic Solution, 0.2% administered BID</description>
    <arm_group_label>Active</arm_group_label>
    <other_name>Squalamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Ophthalmic Solution</intervention_name>
    <description>Placebo Ophthalmic Solution, administered BID</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranibizumab</intervention_name>
    <description>ranibizumab intravitreal injection</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Active</arm_group_label>
    <other_name>Lucentis®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  50 years of age or older

          -  A diagnosis of choroidal neovascularization secondary to age-related macular
             degeneration (AMD) with choroidal neovascularization (CNV) comprising at least 50% of
             the total lesion area in the study eye

          -  Central retinal thickness ≥ 300 μm and presence of subretinal fluid or cystoid edema
             by Optical Coherence Tomography (OCT)

          -  Best Corrected Visual Acuity (BCVA) of 20/40 to 20/320 by Early Treatment Diabetic
             Retinopathy Study (ETDRS) Protocol

        Exclusion Criteria:

          -  Neovascularization secondary to any other condition than AMD in the study eye

          -  Blood occupying greater than 50% of the AMD lesion, or blood &gt; 1.0 sq. mm underlying
             the fovea

          -  PED without associated subretinal fluid and/or cystic retinal changes

          -  Clinical evidence of diabetic retinopathy or diabetic macular edema in the study eye

          -  Confounding ocular conditions in the study eye which will affect interpretation of
             OCT, VA or assessment of macular appearance (e.g., cataract, epiretinal membrane,
             retinal vascular occlusive disease)

          -  Fibrosis or atrophy, retinal epithelial tear in the center of the fovea in the study
             eye or any condition preventing VA improvement

          -  Uncontrolled glaucoma in the study eye, or currently receiving topical glaucoma
             medication in the study eye
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Avner Ingerman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ohr Pharmaceutical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2015</study_first_submitted>
  <study_first_submitted_qc>July 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2015</study_first_posted>
  <last_update_submitted>April 25, 2017</last_update_submitted>
  <last_update_submitted_qc>April 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>Squalamine</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

